tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GNLX Stock Latest News

Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
RatingsGenelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
3d ago
GNLX
Genelux price target raised to $20 from $10 at Maxim
PremiumThe Fly
Genelux price target raised to $20 from $10 at Maxim
4d ago
GNLX
REPL
Genelux initiated with a Buy at Lake Street
PremiumThe Fly
Genelux initiated with a Buy at Lake Street
4d ago
GNLX
Genelux Corp. Lowers Stock Option Exercise Prices
PremiumCompany Announcements
Genelux Corp. Lowers Stock Option Exercise Prices
2M ago
8K
GNLX
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating
PremiumRatings
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating
3M ago
GNLX
Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position
PremiumRatingsPromising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position
3M ago
GNLX
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
Premium
Ratings
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
3M ago
GNLX
Genelux reports Q2 EPS (20c), consensus (22c)
Premium
The Fly
Genelux reports Q2 EPS (20c), consensus (22c)
3M ago
GNLX
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy
PremiumRatings
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy
3M ago
GNLX
Genelux initiated with a Buy at Lucid Capital
PremiumThe Fly
Genelux initiated with a Buy at Lucid Capital
3M ago
GNLX
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead
PremiumRatings
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead
3M ago
GNLX
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
PremiumThe Fly
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
4M ago
GNLX
RANI
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position
PremiumRatingsGenelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position
6M ago
GNLX
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating
Premium
Ratings
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating
6M ago
GNLX
Genelux reports Q1 EPS (21c), consensus (24c)
Premium
The Fly
Genelux reports Q1 EPS (21c), consensus (24c)
6M ago
GNLX
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
PremiumRatings
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
7M ago
GNLX
Genelux reports FY24 EPS (95c), consensus (88c)
PremiumThe Fly
Genelux reports FY24 EPS (95c), consensus (88c)
7M ago
GNLX
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.
PremiumRatings
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.
7M ago
GNLX
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec
PremiumThe Fly
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec
7M ago
GNLX
Genelux announces alignment with FDA of approval pathway for Olvi-Vec
PremiumThe FlyGenelux announces alignment with FDA of approval pathway for Olvi-Vec
7M ago
GNLX
Genelux prices 3M shares at $3.50 in underwritten public offering
Premium
The Fly
Genelux prices 3M shares at $3.50 in underwritten public offering
7M ago
GNLX
One new option listing on February 19th
Premium
The Fly
One new option listing on February 19th
8M ago
GNLX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >